BioSpace News Archive

Cyxone announced that the company has signed an agreement with a UK contract research organization to conduct the six-month toxicology studies with Rabeximod as required ahead of the Phase IIb study.

Phase 1 Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients

Soliton, Inc. announced that it has entered into a Cooperative Development Agreement with Emphysys, an interdisciplinary technology and product development firm just outside Boston, for design and engineering services related to the Company’s acoustical shockwave technology.

Seed Health, a microbial sciences company, today announced a research partnership with digital health company, Atmo Biosciences, to use the world’s first ingestible gas-sensing capsule technology in clinical trials to profile key gases produced within the gut in real-time.

Agilent Technologies Inc. (NYSE: A) has announced that the nomination process to submit proposals to receive an Agilent-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Bryan K. Phillips as chief legal officer.

STI Pharma, LLC today announced that it has appointed Frank Mullery President and CCO.

FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced positive Phase 1b/2 results from an ongoing study in patients with IDH1-mutated gliomas.

Expansion and development of leadership team drives the company’s chemogenetic gene therapy platform toward the clinic in initial core therapeutic areas of chronic neuropathic pain and focal epilepsy

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that more than 40 abstracts, including 18 oral presentations, will be presented during the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition, December 7-10, in Orlando, FL. New data include presentations on Ibrutinib (IMBRUVICA®) plus venetoclax (VENCLEXTA®/ VENCLYXTO®) among others.